grid-line

Tesamorelin

22.2K
Volume
+4900%
Growth
exploding

Turn Trends into Views🚀

Type in a topic to instantly see search volume, difficulty and related topics. All for free.

Free insights powered by
About the Topic

This synthetic peptide is utilized to decrease excess abdominal fat in HIV-infected patients with lipodystrophy by promoting growth hormone production. It is marketed under the brand name Egrifta and is distinguished by its specific application in managing lipodystrophy associated with HIV. The primary beneficiaries of this treatment are HIV-infected individuals experiencing lipodystrophy-related abdominal fat accumulation.

Tesamorelin was discovered on April 30th 2025 and it currently has a search volume of 22.2K with a growth of +4900%.

Key Indicators
Growth
  • Exploding
  • Regular
  • Peaked
Speed
  • Exponential
  • Constant
  • Stationary
Seasonality
  • High
  • Medium
  • Low
Volatility
  • High
  • Average
  • Low
Members Only
Try Exploding Topics Pro
Get Free, Unlimited Access for 7 Days.
Related Topics

Save this topic and build your own trend dashboard.

Available with Exploding Topics Pro, try it now.